Nifty Midcap Select News and Updates

Name: Latest research reports of Colgate-Palmolive (India) Ltd. authored by Sharekhan and published by - Trendlyne research reports.
Item: Colgate-Palmolive (India) Ltd.
Rating: 5
Author: Sharekhan

Keep track of all breaking news on Nifty Midcap Select from all sources in a single place.

Load latest

Colgate-Palmolive (India) Ltd.

27 May 2025

2398.40

0.69%

Colgate Palmolive Dividend: Last Day To Buy Shares To Qualify Details Here

NDTV Profit

Colgate Palmolive's board announced a second interim dividend of Rs 27 per share for financial year 2025.

Number of FII/FPI investors decreased from 943 to 892 in Mar 2025 qtr

Ashok Leyland Ltd.

27 May 2025

233.99

-0.23%

Ashok Leyland Aims To Make EV Arm Switch Mobility Fund Own Capex

NDTV Profit

CEO Shenu Agarwal describes the decision to issue a bonus as a gesture to 'reward our shareholders further'.

Promoters pledged 11.05% of shares in last quarter. Total pledge stands at 41.15% of promoter holdings

Broker's call: Ashok Leyland (Outperform)

Business Line | 26 May 2025 5 more

Colgate-Palmolive (India) Ltd.

27 May 2025

2398.40

0.69%

Soft Q4; recovery to be gradual

Buy: Colgate-Palmolive (India) ...

Recommendation Target

Sharekhan

Colgate’s Q4FY25 performance was muted owing to soft demand in urban markets and heightened competitive intensity. Standalone revenues declined by 1.8% y-o-y to Rs. 1,463 crore, missing our expectation of Rs. 1,520 crore, with toothpaste volumes flat y-o-y.

Colgate-Palmolive (I.. has an average target of 2729.25 from 8 brokers.

Aurobindo Pharma Ltd.

27 May 2025

1105.30

-0.40%

Aurobindo Pharma (ARBP IN) Q4FY25 Result Update Resumption...

Buy: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

Aurobindo Pharma's (ARBP) Q4FY25 EBITDA of Rs17.9bn (up 6% YoY) was in line with our estimate. FY26 guidance of high single digit revenue growth ex gRevlimid with flat margins was below our estimate. Resultant our FY26 and FY27E EPS stands reduced by 4-5%. Other expenses remained elevated on the back of higher PenG-related operational cost and supply disruptions due to...

Aurobindo Pharma Ltd. has an average target of 1493.80 from 10 brokers.

Bharat Heavy Electricals Ltd.

26 May 2025

251.80

-0.22%

No cause of worry, infection severity mild: ICMR DG amid Covid cases uptick

Business Standard

Amid an uptick in Covid cases in some parts of the country, Director General of the Indian Council of Medical Research (ICMR) Dr Rajiv Behl Monday said the severity of infections as of now is generally mild and there was no cause for worry. Speaking about new Covid variants being traced, he said genome sequencing of samples in the west and south have shown that the new variants are not severe and are Omicron sub-variants. These are LF.7, XFG, JN.1 and NB. 1.8.1. The first three are more prevalent, Dr Bhel said. "Samples from other places are being sequenced and we will know in a day or two if there are more variants." The ICMR DG said there has been an uptick in cases --first from the south, then west and now from northern India. All these cases are being monitored through the Integrated Disease Surveillance Programme (IDSP). Besides that, ICMR's nationwide respiratory virus sentinel surveillance network is keeping a watch on emerging infections and pathogens, he said. "Whenever c

Bharat Heavy Electricals Ltd. has gained 28.84% in the last 3 Months

Lupin Ltd.

26 May 2025

1954.00

0.51%

Lupin signs licensing deal with SteinCares for ranibizumab in LatAm

Business Standard

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding Mexico and Argentina

Number of FII/FPI investors increased from 964 to 979 in Mar 2025 qtr.

Lupin inks licence agreement to commercialise biosimilar in Latin America

Business Line | 26 May 2025

Ashok Leyland Ltd.

26 May 2025

233.99

-0.23%

Ashok Leyland (BUY): Healthy show to continue; retain BUY

Buy: Ashok Leyland Ltd.

Target

BOB Capital Markets Ltd.

Q4FY25 revenue grew 6%/26% YoY/QoQ to Rs 119.1bn, aided by volume gains of 4%/27% YoY/QoQ, while realisations stay put

Ashok Leyland Ltd. is trading below its 30 day SMA of 236.4

Colgate-Palmolive (India) Ltd.

25 May 2025

2398.40

0.69%

Pressure plaque steadily builds on Colgate-Palmolive's Q4 performance

Business Standard

Can it fill the cavity of doubt with its premium strategy? Experts weigh in

Colgate-Palmolive (I.. has an average target of 2729.25 from 8 brokers.

Vodafone Idea Ltd.

25 May 2025

6.56

-0.61%

Softbank's Son Floats Idea of US-Japan Sovereign Wealth Fund: FT

NDTV Profit

Son's proposed $300 billion US-Japan fund would target tech and infrastructure, offering potential retail investor access and alternative revenue for Treasury